JPH09507502A - raf遺伝子発現のアンチセンスオリゴヌクレオチド調節 - Google Patents
raf遺伝子発現のアンチセンスオリゴヌクレオチド調節Info
- Publication number
- JPH09507502A JPH09507502A JP8501257A JP50125796A JPH09507502A JP H09507502 A JPH09507502 A JP H09507502A JP 8501257 A JP8501257 A JP 8501257A JP 50125796 A JP50125796 A JP 50125796A JP H09507502 A JPH09507502 A JP H09507502A
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- raf
- oligonucleotides
- expression
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ヒトrafをコードするmRNAを標的とし、かつraf発現を阻害しうる 、8から50ヌクレオチド長さのオリゴヌクレオチド。 2.ヒトA−rafをコードするmRNAを標的とする、請求項1記載のオリゴ ヌクレオチド。 3.配列番号29、37または40を有する、請求項2記載のオリゴヌクレオチ ド。 4.ヒトc−rafをコードするmRNAを標的とする、請求項1記載のオリゴ ヌクレオチド。 5.ヒトc−rafをコードするmRNAの翻訳開始部位、3’非翻訳領域また は5’非翻訳領域を標的とする、請求項4記載のオリゴヌクレオチド。 6.少なくとも1つのホスホロチオエート結合を有する、請求項1記載のオリゴ ヌクレオチド。 7.オリゴヌクレオチドのヌクレオチドユニットの少なくとも1つが糖部分の2 ’位で修飾されている、請求項1記載のオリゴヌクレオチド。 8.前記糖部分の2’位における修飾が2’−O−アルキルまたは2’−フルオ ロ修飾である、請求項7記載のオリゴヌクレオチド。 9.薬学的に許容しうる担体中の、請求項1記載のオリゴヌクレオチド。 10.配列番号2、6、8、12、17、20、21、22、23、24、25 、26または27を含む、請求項5記載のオリゴヌクレオチド。 11.配列番号8を有するオリゴヌクレオチド。 12.少なくとも1つの2’−O−メチル修飾を含む、請求項11記載のオリゴ ヌクレオチド。 13.ヒトrafをコードするmRNAを標的とし、標的親和性を増強するよう に修飾されている少なくとも1つのヌクレオチドを有する第1の領域およびRN AseHの基質である第2の領域を含む、8から50ヌクレオチド長さのキメラ オリゴヌクレオチドであって、raf発現を阻害しうることを特徴とするキメラ オリゴヌクレオチド。 14.標的親和性を増強するように修飾されているヌクレオチドが糖部分の2’ 位で修飾されている、請求項13記載のオリゴヌクレオチド。 15.糖部分の2’位における修飾が2’−O−アルキルまたは2’−フルオロ 修飾である、請求項14記載のオリゴヌクレオチド。 16.RNAseHの基質である領域が少なくとも1つの2’−デオキシヌクレ オチドを含む、請求項13記載のオリゴヌクレオチド。 17.少なくとも1つのホスホロチオエート結合を有する、請求項13記載のオ リゴヌクレオチド。 18.ヒトc−rafをコードするmRNAの翻訳開始部位、3’非翻訳領域ま たは5’非翻訳領域を標的とする、請求項13記載のオリゴヌクレオチド。 19.薬学的に許容しうる担体中の、請求項13記載のオリゴヌクレオチド。 20.配列番号8、21、24、25、26または27を含む、請求項17記載 のオリゴヌクレオチド。 21.標的親和性を増強するように修飾されている少なくとも1つのヌクレオチ ドを有する第1の領域およびRNAseHの基質である第2の領域を含む、配列 番号8を有するキメラオリゴヌクレオチドであって、raf発現を阻害しうるこ とを特徴とするキメラオリゴヌクレオチド。 22.ヒトrafの発現を阻害する方法であって、ヒトrafを発現する組織ま たは細胞を、ヒトrafをコードするmRNAを標的とかつraf発現を阻害し うる、8から50ヌクレオチド長さのオリゴヌクレオチドと接触させることを含 む方法。 23.前記オリゴヌクレオチドがヒトA−rafをコードするmRNAを標的と する、請求項22記載の方法。 24.前記オリゴヌクレオチドがヒトc−rafをコードするmRNAを標的と する、請求項22記載の方法。 25.前記オリゴヌクレオチドが、ヒトc−rafをコードするmRNAの翻訳 開始部位、3’非翻訳領域または5’非翻訳領域を標的とする、請求項24記載 の方法。 26.前記オリゴヌクレオチドが配列番号2、6、8、12、17、20、21 、 22、23、24、25、26または27を含む、請求項25記載の方法。 27.前記ヒトrafの発現が異常な発現である、請求項22記載の方法。 28.前記オリゴヌクレオチドがキメラオリゴヌクレオチドである、請求項22 記載の方法。 29.前記キメラオリゴヌクレオチドが配列番号8、21、24、25、26ま たは27を含む、請求項28記載の方法。 30.前記オリゴヌクレオチドが少なくとも1つのホスホロチオエート結合を有 する、請求項22記載の方法。 31.ヒトrafの発現を阻害する方法であって、ヒトrafを発現する組織ま たは細胞を配列番号8を有するオリゴヌクレオチドと接触させることを含む方法 。 32.細胞の過増殖を阻害する方法であって、過増殖細胞をヒトrafをコード するmRNAを標的としかつraf発現を阻害しうる、8から50ヌクレオチド 長さのオリゴヌクレオチドと接触させることを含む方法。 33.前記オリゴヌクレオチドがヒトA−rafをコードするmRNAを標的と する、請求項32記載の方法。 34.前記オリゴヌクレオチドがヒトc−rafをコードすろmRNAを標的と する、請求項32記載の方法。 35.前記オリゴヌクレオチドが、ヒトc−rafをコードするmRNAの翻訳 開始部位、3’非翻訳領域または5’非翻訳領域を標的とする、請求項34記載 の方法。 36.前記オリゴヌクレオチドが配列番号2、6、8、12、17、20、21 、22、23、24、25、26または27を含む、請求項35記載の方法。 37.前記オリゴヌクレオチドがキメラオリゴヌクレオチドである、請求項32 記載の方法。 38.前記キメラオリゴヌクレオチドが配列番号8、21、24、25、26ま たは27を含む、請求項37記載の方法。 39.前記オリゴヌクレオチドが少なくとも1つのホスホロチオエート結合を有 する、請求項32記載の方法。 40.細胞の過増殖を阻害する方法であって、過増殖細胞を配列番号8を有する オリゴヌクレオチドと接触させることを含む方法。 41.異常な増殖性状態を処置する方法であって、異常な増殖性状態を有すると 疑われる患者または前記患者の細胞、組織もしくは体液を、ヒトrafをコード するmRNAを標的としかつraf発現を阻害しうる、8から50ヌクレオチド 長さのオリゴヌクレオチドと接触させることを含む方法。。 42.状態が過増殖性疾患である、請求項41記載の方法。 43.過増殖性疾患が癌、再狭窄、乾癬またはT−細胞の活性化および成長によ り特徴づけられる疾患である、請求項42記載の方法。 44.前記オリゴヌクレオチドがヒトA−rafをコードするmRNAを標的と する、請求項41記載の方法。 45.前記オリゴヌクレオチドがヒトc−rafをコードするmRNAを標的と する、請求項41記載の方法。 46.前記オリゴヌクレオチドがヒトc−rafをコードするmRNAの3’非 翻訳領域または5’非翻訳領域を標的とする、請求項45記載の方法。 47.前記オリゴヌクレオチドが配列番号2、6、8、12、17、20、21 、22、23、24、25、26または27を含む、請求項46記載の方法。 48.前記オリゴヌクレオチドがキメラオリゴヌクレオチドである、請求項41 記載の方法。 49.前記キメラオリゴヌクレオチドが配列番号8、21、24、25、26ま たは27を含む、請求項48記載の方法。 50.前記オリゴヌクレオチドが少なくとも1つのホスホロチオエート結合を有 する、請求項41記載の方法。 51.異常な増殖性状態を処置する方法であって、異常な増殖性状態を有すると 疑われる患者、または前記患者の細胞、組織もしくは体液を、配列番号8を有す るオリゴヌクレオチドと接触させることを含む方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/250,856 US5563255A (en) | 1994-05-31 | 1994-05-31 | Antisense oligonucleotide modulation of raf gene expression |
US08/250,856 | 1994-05-31 | ||
US250,856 | 1994-05-31 | ||
PCT/US1995/007111 WO1995032987A1 (en) | 1994-05-31 | 1995-05-31 | ANTISENSE OLIGONUCLEOTIDE MODULATION OF raf GENE EXPRESSION |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000008654A Division JP3121599B2 (ja) | 1994-05-31 | 2000-01-18 | raf遺伝子発現のアンチセンスオリゴヌクレオチド調節 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09507502A true JPH09507502A (ja) | 1997-07-29 |
JP3231779B2 JP3231779B2 (ja) | 2001-11-26 |
Family
ID=22949424
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50125796A Expired - Lifetime JP3231779B2 (ja) | 1994-05-31 | 1995-05-31 | raf遺伝子発現のアンチセンスオリゴヌクレオチド調節 |
JP2000008654A Expired - Fee Related JP3121599B2 (ja) | 1994-05-31 | 2000-01-18 | raf遺伝子発現のアンチセンスオリゴヌクレオチド調節 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000008654A Expired - Fee Related JP3121599B2 (ja) | 1994-05-31 | 2000-01-18 | raf遺伝子発現のアンチセンスオリゴヌクレオチド調節 |
Country Status (12)
Country | Link |
---|---|
US (4) | US5563255A (ja) |
EP (1) | EP0763052B1 (ja) |
JP (2) | JP3231779B2 (ja) |
AT (1) | ATE280772T1 (ja) |
AU (1) | AU689267B2 (ja) |
CA (1) | CA2191795C (ja) |
DE (1) | DE69533697T2 (ja) |
FI (1) | FI964792A (ja) |
HU (1) | HUT76675A (ja) |
IL (1) | IL113804A (ja) |
NO (1) | NO965080D0 (ja) |
WO (1) | WO1995032987A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002535015A (ja) * | 1999-01-29 | 2002-10-22 | エイブイアイ バイオファーマ, インコーポレイテッド | 標的rnaを検出するための非侵襲性方法 |
JP2006528986A (ja) * | 2003-05-20 | 2006-12-28 | バイエル、ファーマシューテイカルズ、コーポレイション | Pdgfrによって仲介される病気のためのジアリール尿素 |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465188B1 (en) * | 1990-06-11 | 2002-10-15 | Gilead Sciences, Inc. | Nucleic acid ligand complexes |
US5981731A (en) * | 1994-05-31 | 1999-11-09 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of B-raf gene expression |
US6410518B1 (en) * | 1994-05-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
US6358932B1 (en) * | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
US6090626A (en) * | 1994-05-31 | 2000-07-18 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of raf gene expression |
US6391636B1 (en) | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
KR100211178B1 (ko) * | 1994-05-31 | 1999-07-15 | 파샬 비. 린네 | 라프유전자 발현의 안티센스 올리고뉴클레오티드 조절 |
US5744362A (en) * | 1994-05-31 | 1998-04-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US6608035B1 (en) * | 1994-10-25 | 2003-08-19 | Hybridon, Inc. | Method of down-regulating gene expression |
US8071737B2 (en) * | 1995-05-04 | 2011-12-06 | Glead Sciences, Inc. | Nucleic acid ligand complexes |
US6229002B1 (en) | 1995-06-07 | 2001-05-08 | Nexstar Pharmaceuticlas, Inc. | Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
US6699843B2 (en) * | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
CA2227989A1 (en) * | 1995-08-01 | 1997-02-13 | Karen Ophelia Hamilton | Liposomal oligonucleotide compositions |
GB9519109D0 (en) * | 1995-09-19 | 1995-11-22 | Ciba Geigy Ag | Compositions |
GB9604669D0 (en) * | 1996-03-05 | 1996-05-01 | Ciba Geigy Ag | Chemical compounds |
US5744460A (en) * | 1996-03-07 | 1998-04-28 | Novartis Corporation | Combination for treatment of proliferative diseases |
JP2000504023A (ja) * | 1996-04-03 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | 癌治療方法 |
US6027892A (en) * | 1996-12-30 | 2000-02-22 | Chang Esther H | Compositions and methods for reducing radiation and drug resistance in cells |
US6803360B1 (en) | 1996-12-30 | 2004-10-12 | Georgetown University | Compositions and methods for reducing radiation and drug resistance in cells |
US6127533A (en) * | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
US6576752B1 (en) | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
WO1998042722A1 (en) | 1997-03-21 | 1998-10-01 | President And Fellows Of Harvard College | Antisense inhibition of angiogenin expression |
US6126965A (en) * | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
US7262173B2 (en) * | 1997-03-21 | 2007-08-28 | Georgetown University | Chemosensitizing with liposomes containing oligonucleotides |
US20030036516A1 (en) * | 1997-09-10 | 2003-02-20 | Sudhir Agrawal | Method for using oligonucleotides having modified cpg dinucleotides |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
US6492111B1 (en) * | 1998-11-25 | 2002-12-10 | Isis Pharmaceuticals, Inc. | In situ binary synthesis of biologically effective molecules |
US6114517A (en) * | 1998-12-10 | 2000-09-05 | Isis Pharmaceuticals Inc. | Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules |
CA2371814C (en) * | 1999-02-26 | 2014-05-27 | The University Of British Columbia | Trpm-2 antisense therapy |
FR2790955B1 (fr) * | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
US6147200A (en) * | 1999-08-19 | 2000-11-14 | Isis Pharmaceuticals, Inc. | 2'-O-acetamido modified monomers and oligomers |
US6677445B1 (en) | 1999-08-27 | 2004-01-13 | Chiron Corporation | Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
US7569551B2 (en) * | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
DE10020138A1 (de) * | 2000-04-14 | 2001-10-31 | Ulf R Rapp | Nukleinsäure codierend für zumindest eine raf Teilsequenz mit einer MEKK1 Bindungsstelle |
PT1295611E (pt) * | 2000-06-20 | 2010-09-14 | Dainippon Sumitomo Pharma Co | Preparações para transferência de oligonucleótidos |
US6867349B2 (en) * | 2000-07-31 | 2005-03-15 | Regents Of The University Of Minnesota | Inhibition of gene expression using polynucleotide analogues |
US20070021360A1 (en) * | 2001-04-24 | 2007-01-25 | Nyce Jonathan W | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase |
PT1407787E (pt) * | 2001-06-20 | 2009-07-07 | Koken Kk | Método de promoção da transferência de ácido nucleico |
EP1552002A4 (en) * | 2002-06-18 | 2006-02-08 | Archemix Corp | APTAMER TOXIN MOLECULES AND METHOD FOR THEIR USE |
US20040249130A1 (en) * | 2002-06-18 | 2004-12-09 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
EP1568769A4 (en) * | 2002-11-25 | 2008-08-06 | Masafumi Matsuo | ENA-NUCLEIC ACID MEDICAMENTS THAT CHANGE SPLICING IN THE MRNA PRESETTER |
EP1696034A4 (en) * | 2003-12-19 | 2006-12-27 | Dainippon Sumitomo Pharma Co | NUCLEIC ACID TRANSFER METHOD |
WO2005094899A1 (en) | 2004-04-02 | 2005-10-13 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
US8101350B1 (en) * | 2004-05-24 | 2012-01-24 | Isis Pharmaceuticals, Inc. | Modulation of exportin 5 expression |
US20090062184A1 (en) * | 2005-03-24 | 2009-03-05 | Dainippon Sumitomo Pharma Co., Ltd. | Fine particulate preparation comprising complex of nucleic acid molecule and collagen |
US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
WO2007014150A2 (en) * | 2005-07-22 | 2007-02-01 | Neopharm, Inc. | Method of administering liposomes containing oligonucleotides |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
SI2010528T1 (en) | 2006-04-19 | 2018-02-28 | Novartis Ag | 6-O-substituted benzoxazole and benzothiazole compounds and procedures for inhibiting CSF-1R signaling |
WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
PL2336120T3 (pl) | 2007-01-10 | 2014-12-31 | Msd Italia Srl | Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP) |
MX2009009304A (es) | 2007-03-01 | 2009-11-18 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso. |
CA2685967A1 (en) | 2007-05-21 | 2008-11-21 | Novartis Ag | Csf-1r inhibitors, compositions, and methods of use |
CA2690191C (en) | 2007-06-27 | 2015-07-28 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
PE20121172A1 (es) | 2009-10-14 | 2012-09-05 | Merck Sharp & Dohme | Piperidinas sustituidas con actividad en la hdm2 |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
CA2824843A1 (en) | 2010-02-04 | 2011-08-11 | Ico Therapeutics Inc. | Dosing regimens for treating and preventing ocular disorders using c-raf antisense |
WO2011112516A1 (en) | 2010-03-08 | 2011-09-15 | Ico Therapeutics Inc. | Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides |
BR112012023021A2 (pt) | 2010-03-16 | 2016-05-31 | Dana Farber Cancer Inst Inc | compostos de indazol e seus usos |
US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
CA2805265A1 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
CA2807307C (en) | 2010-08-17 | 2021-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
EP2632472B1 (en) | 2010-10-29 | 2017-12-13 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
IN2013MN02170A (ja) | 2011-04-21 | 2015-06-12 | Piramal Entpr Ltd | |
WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
EP3569598A1 (en) | 2011-11-17 | 2019-11-20 | Dana Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
EP2844261B1 (en) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
WO2014052563A2 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
MX363243B (es) | 2012-11-28 | 2019-03-14 | Merck Sharp & Dohme | Composiciones para tratar cáncer y usos de dichas composiciones. |
BR112015013611A2 (pt) | 2012-12-20 | 2017-11-14 | Merck Sharp & Dohme | composto, e, composição farmacêutica |
EP2951180B1 (en) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
ES2676734T3 (es) | 2013-10-18 | 2018-07-24 | Syros Pharmaceuticals, Inc. | Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
JP6854762B2 (ja) | 2014-12-23 | 2021-04-07 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼ7(cdk7)の阻害剤 |
JP6861166B2 (ja) | 2015-03-27 | 2021-04-21 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
CA2996978A1 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
MX2019012233A (es) | 2017-04-13 | 2020-01-14 | Aduro Biotech Holdings Europe Bv | Anticuerpos anti-sirpa. |
WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
US20210277009A1 (en) | 2018-08-07 | 2021-09-09 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5190931A (en) * | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US4871838A (en) * | 1985-07-23 | 1989-10-03 | The Board Of Rijks Universiteit Leiden | Probes and methods for detecting activated ras oncogenes |
US5194428A (en) * | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
US5264423A (en) * | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5276019A (en) * | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5004810A (en) * | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
US5098890A (en) * | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
US5135917A (en) * | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
US5541307A (en) * | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
WO1994008003A1 (en) * | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
WO1993004170A1 (en) * | 1991-08-23 | 1993-03-04 | The United States Of America Represented By The Secretary, Department Of Health And Human Services | Raf protein kinase therapeutics |
JPH08506000A (ja) * | 1991-09-16 | 1996-07-02 | アメリカ合衆国 | C−raf−1遺伝子検出方法 |
WO1994015645A1 (en) * | 1992-12-31 | 1994-07-21 | Texas Biotechnology Corporation | Antisense molecules directed against genes of the raf oncogene family |
WO1994023755A1 (en) * | 1993-04-09 | 1994-10-27 | Board Of Regents Of The University Of Nebraska | Novel methods and compositions for the treatment of ras-activated cancer with heterotypic anti-raf antisense oligonucleotides |
WO1996019240A1 (en) * | 1994-12-21 | 1996-06-27 | Novartis Ag | Oligonucleotide-dendrimer conjugates |
-
1994
- 1994-05-31 US US08/250,856 patent/US5563255A/en not_active Expired - Lifetime
-
1995
- 1995-05-21 IL IL11380495A patent/IL113804A/xx not_active IP Right Cessation
- 1995-05-31 AT AT95922217T patent/ATE280772T1/de not_active IP Right Cessation
- 1995-05-31 AU AU26982/95A patent/AU689267B2/en not_active Expired - Fee Related
- 1995-05-31 HU HU9603277A patent/HUT76675A/hu unknown
- 1995-05-31 DE DE69533697T patent/DE69533697T2/de not_active Expired - Lifetime
- 1995-05-31 JP JP50125796A patent/JP3231779B2/ja not_active Expired - Lifetime
- 1995-05-31 EP EP95922217A patent/EP0763052B1/en not_active Expired - Lifetime
- 1995-05-31 CA CA002191795A patent/CA2191795C/en not_active Expired - Lifetime
- 1995-05-31 WO PCT/US1995/007111 patent/WO1995032987A1/en active IP Right Grant
-
1996
- 1996-11-28 NO NO965080A patent/NO965080D0/no not_active Application Discontinuation
- 1996-11-29 FI FI964792A patent/FI964792A/fi unknown
-
2000
- 2000-01-18 JP JP2000008654A patent/JP3121599B2/ja not_active Expired - Fee Related
-
2011
- 2011-07-18 US US13/185,406 patent/US20120149755A1/en not_active Abandoned
-
2012
- 2012-11-15 US US13/678,432 patent/US20130079387A1/en not_active Abandoned
-
2013
- 2013-07-31 US US13/956,213 patent/US20140187601A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002535015A (ja) * | 1999-01-29 | 2002-10-22 | エイブイアイ バイオファーマ, インコーポレイテッド | 標的rnaを検出するための非侵襲性方法 |
JP2006528986A (ja) * | 2003-05-20 | 2006-12-28 | バイエル、ファーマシューテイカルズ、コーポレイション | Pdgfrによって仲介される病気のためのジアリール尿素 |
Also Published As
Publication number | Publication date |
---|---|
CA2191795C (en) | 2003-06-10 |
HUT76675A (en) | 1997-10-28 |
EP0763052B1 (en) | 2004-10-27 |
FI964792A0 (fi) | 1996-11-29 |
JP2000152797A (ja) | 2000-06-06 |
US20130079387A1 (en) | 2013-03-28 |
CA2191795A1 (en) | 1995-12-07 |
AU2698295A (en) | 1995-12-21 |
JP3121599B2 (ja) | 2001-01-09 |
NO965080L (no) | 1996-11-28 |
DE69533697D1 (de) | 2004-12-02 |
JP3231779B2 (ja) | 2001-11-26 |
IL113804A (en) | 2000-12-06 |
US5563255A (en) | 1996-10-08 |
HU9603277D0 (en) | 1997-01-28 |
US20120149755A1 (en) | 2012-06-14 |
US20140187601A1 (en) | 2014-07-03 |
WO1995032987A1 (en) | 1995-12-07 |
DE69533697T2 (de) | 2006-02-09 |
EP0763052A4 (en) | 1998-10-14 |
ATE280772T1 (de) | 2004-11-15 |
IL113804A0 (en) | 1995-08-31 |
FI964792A (fi) | 1996-11-29 |
AU689267B2 (en) | 1998-03-26 |
EP0763052A1 (en) | 1997-03-19 |
NO965080D0 (no) | 1996-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09507502A (ja) | raf遺伝子発現のアンチセンスオリゴヌクレオチド調節 | |
US5656612A (en) | Antisense oligonucleotide modulation of raf gene expression | |
JP3054745B2 (ja) | raf遺伝子発現のアンチセンスオリゴヌクレオチド調節 | |
CA2174315C (en) | Oligonucleotide modulation of multidrug resistance-associated protein | |
US6358932B1 (en) | Antisense oligonucleotide inhibition of raf gene expression | |
JP4643906B2 (ja) | 遺伝子発現の標的化阻害のための合成二本鎖オリゴヌクレオチド | |
KR20020097241A (ko) | 스플라이스-영역 안티센스 조성물 및 방법 | |
JPH10507635A (ja) | 遺伝子発現をダウンレギュレートするための2’−置換オリゴヌクレオチドの使用 | |
US6001991A (en) | Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression | |
KR20220024153A (ko) | 안지오포이에틴 유사 7(angptl7) 관련 질환의 치료 | |
US6090626A (en) | Antisense oligonucleotide modulation of raf gene expression | |
KR100211178B1 (ko) | 라프유전자 발현의 안티센스 올리고뉴클레오티드 조절 | |
WO1997044656A1 (en) | Compositions and methods for modulating type i interleukin-1 receptor expression | |
JP4690649B2 (ja) | 標的化された遺伝子発現阻害のための新規なオリゴリボヌクレオチド誘導体 | |
US20040171564A1 (en) | Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression | |
AU714142B2 (en) | Antisense oligonucleotide modulation of RAF gene expression | |
US5807838A (en) | Oligonucleotide modulation of multidrug resistance-associated protein | |
WO2023192828A2 (en) | Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases | |
AU710972B2 (en) | Oligonucleotide modulation of protein kinase C | |
JP2002095479A (ja) | オーロラ2キナーゼ阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080914 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090914 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100914 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110914 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110914 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120914 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120914 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130914 Year of fee payment: 12 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |